

Client: Example Client ABC123  
123 Test Drive  
Salt Lake City, UT 84108  
UNITED STATES

Physician: Doctor, Example

**Patient: Patient, Example**

**DOB:** 5/11/1989  
**Gender:** Female  
**Patient Identifiers:** 01234567890ABCD, 012345  
**Visit Number (FIN):** 01234567890ABCD  
**Collection Date:** 01/01/2017 12:34

**Hepatitis B Virus (HBV) Drug Resistance, Genotype and BCP/Precore Mutations by Sequencing**

ARUP test code 2013476

HBV Genotype	A
HBV Polymerase Mutations	NOT DETECTED
HBV Precore Mutations	NOT OBTAINED
HBV Basal Core Promoter (BCP) Mutations	NOT OBTAINED

**H=High, L=Low, \*=Abnormal, C=Critical**

Unless otherwise indicated, testing performed at:

"Not obtained" indicates test was performed, however, poor sequence data was obtained for the BCP and/or the PreCore regions. Therefore, the presence or absence of mutations could not be determined. Possible reasons for poor sequence are low viral load or polymorphisms in the primer binding site.

Antiviral drugs Predicted	Resistance	Mutations
Polymerase Inhibitors	!	!
3TC (lamivudine or Epivir)	!	NO!
LDT (telbivudine or Tyzeka)	!	NO!
FCV (famciclovir or Famvir)	!	NO!
ADV (adefovir or Hepsera)	!	NO!
ETV (entecavir or Baraclude)	!	NO!

Precore and BCP Mutations

Precore (TAG)	N/A
BCP	N/A

OTHER MUTATIONS DETECTED:

POLYMERASE:	V173M/V
PRECORE:	N/A
BCP:	N/A

The method used in this test is PCR and sequencing of the pol gene and BCP/precure region of HBV. A resistance profile for tenofovir has not yet been established.

This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics Infectious Disease. It has not been cleared or approved by the U.S. Food and Drug Administration. The FDA has determined that such clearance or approval is not necessary. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes. The method used in this test is PCR and sequencing of the pol gene and BCP/precure region of HBV. A resistance profile for tenofovir has not yet been established.

This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics Infectious Disease. It has not been cleared or approved by the U.S. Food and Drug Administration. The FDA has determined that such clearance or approval is not necessary. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes. Performed at Quest Diagnostics Infectious Disease, 33608 Ortega Highway, San Juan Capistrano, CA 92675, Hollis J. Batterman MD, Director, CLIA 05D0644251

**H=High, L=Low, \*=Abnormal, C=Critical**

Unless otherwise indicated, testing performed at:

**ARUP LABORATORIES | 800-522-2787 | aruplab.com**  
500 Chipeta Way, Salt Lake City, UT 84108-1221  
Tracy I. George, MD, Laboratory Director

Patient: Patient, Example  
ARUP Accession: 18-331-105020  
Patient Identifiers: 01234567890ABCD, 012345  
Visit Number (FIN): 01234567890ABCD  
Page 2 of 3 | Printed: 12/9/2020 7:30:44 AM  
4848

VERIFIED/REPORTED DATES

Procedure	Accession	Collected	Received	Verified/Reported
HBV Genotype	18-331-105020	11/27/2018 10:36:00 AM	11/27/2018 10:36:11 AM	11/27/2018 5:54:00 PM
HBV Polymerase Mutations	18-331-105020	11/27/2018 10:36:00 AM	11/27/2018 10:36:11 AM	11/27/2018 5:54:00 PM
HBV Precore Mutations	18-331-105020	11/27/2018 10:36:00 AM	11/27/2018 10:36:11 AM	11/27/2018 5:54:00 PM
HBV Basal Core Promoter (BCP) Mutations	18-331-105020	11/27/2018 10:36:00 AM	11/27/2018 10:36:11 AM	11/27/2018 5:54:00 PM

END OF CHART

H=High, L=Low, \*=Abnormal, C=Critical

Unless otherwise indicated, testing performed at:

**ARUP LABORATORIES | 800-522-2787 | aruplab.com**  
500 Chipeta Way, Salt Lake City, UT 84108-1221  
Tracy I. George, MD, Laboratory Director

Patient: Patient, Example  
ARUP Accession: 18-331-105020  
Patient Identifiers: 01234567890ABCD, 012345  
Visit Number (FIN): 01234567890ABCD  
Page 3 of 3 | Printed: 12/9/2020 7:30:44 AM  
4848